138423-86-6Relevant articles and documents
Stereoselective Double Alkylation of Ethyl N-Boc-pyroglutamate
Ezquerra, Jesus,Pedregal, Concepcion,Rubio, Almudena,Vaquero, Juan Jose,Matia, Maria Paz,et al.
, p. 4327 - 4331 (1994)
-
As hepatitis c inhibitor spiro compound and its use in medicine
-
Paragraph 1061-1063, (2017/12/28)
The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 152-153, (2012/04/10)
This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds